# T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

> **NCT04611126** · PHASE1,PHASE2 · TERMINATED · sponsor: **Inge Marie Svane** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Ovarian Cancer
- Metastatic Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Cyclophosphamid
- **DRUG:** Fludarabine Phosphate
- **BIOLOGICAL:** Tumor Infiltrating Lymphocytes infusion
- **DRUG:** Nivolumab
- **DRUG:** Relatlimab

## Key facts

- **NCT ID:** NCT04611126
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-22
- **Primary completion:** 2024-03-03
- **Final completion:** 2024-03-03
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04611126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04611126, "T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04611126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*